Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05743075
Other study ID # RPL554-CPC001
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 10, 2023
Est. completion date February 1, 2025

Study information

Verified date February 2023
Source Nuance Pharma (shanghai) Co., Ltd
Contact Mengde Wang
Phone 86-21-32035318
Email mengde.wang@nuancepharma.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical study, which aims to evaluate the efficacy, safety, and PK characteristics of Ensifentrine 3 mg twice daily (BID) for 24 weeks treatment of moderate to severe COPD.


Description:

The study is divided into 3 periods, a screening/run-in period (run-in for 28 days), a treatment period (24 weeks), and a follow-up period (1 week after the end-of-treatment visit). The qualified subjects will be randomly assigned to the Ensifentrine group or placebo group in a ratio of 5:3, stratified by maintenance therapy in a stable background long-acting muscarinic antagonist (LAMA) or long-acting β2 agonist (LABA) (yes or no) and smoking status (current or past smokers). The Ensifentrine group will receive Ensifentrine 3mg BID nebulizer, and the placebo group will receive placebo nebulizer. The treatment will be lasted given for 24 weeks in both groups. During treatment, lung function, COPD symptoms, quality of life and other parameters of subjects will be assessed at baseline, week 6, 12, and 24, and the safety will also be assessed over 24-week treatment period and the follow-up period. PK characteristics and dose-response relationship of Ensifentrine will be analyzed for all patients using sparse sampling.


Recruitment information / eligibility

Status Recruiting
Enrollment 488
Est. completion date February 1, 2025
Est. primary completion date November 1, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: 1. Patient must be 40 to 80 years of age inclusive, at the time of Screening, male or female; 2. Current or former cigarette smokers with a history of cigarette smoking = 10 pack-years; 3. Patients with a clear clinical history of COPD and related symptoms prior to screening; 4. Patients with moderately to severe COPD: Pre- and Post- salbutamol FEV1/FVC ratio < 0.70; and Post-salbutamol FEV1 = 30% and = 70% of predicted 5. A score of =2 on the Modified Medical Research Council Dyspnea Scale at screening; 6. Patients on no maintenance/background therapy or patients on stable maintenance as either LAMA or LABA therapy. 7. Short-acting ß2 agonists (SABAs) should be withheld for at least 6 hours prior to initiation of any spirometry; 8. Female subjects of childbearing potential must have a negative blood pregnancy test 7 days prior to randomization and not be pregnant or lactating. Female subjects of childbearing potential and male subjects with partners of childbearing potential are required to use at least one effective contraceptive method (such as intrauterine contraceptive device, contraceptives or condom) from the screening period, throughout the study period and for at least 30 days after the last dose of blinded investigational product. Exclusion Criteria: 1. History of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation; 2. Hospitalizations for COPD, pneumonia, or Corona Virus Disease 2019 (COVID-19) in the 12 weeks prior to Screening and/or COPD exacerbation, Newly-occurring pneumonia, a positive COVID-19 test result indicating an active infection before Screening; 3. Patients with lower respiratory tract infection occurred and not resolved within 6 weeks prior to screening and/or prior to randomization; 4. COPD exacerbation requiring oral or parenteral (intravenous, subcutaneous, or intramuscular injection) steroids within 3 months prior to screening; 5. Previous lung resection, OR lung reduction surgery within 1 year of screening; 6. Patients with long term of oxygen use;. 7. Patients with pulmonary rehabilitation; 8. Patients with other respiratory disorders including, but not limited to, current diagnosis of asthma, active tuberculosis, lung cancer, sarcoidosis, pulmonary fibrosis, interstitial lung disease, unstable sleep apnea, known alpha-1 antitrypsin deficiency, cor pulmonale, clinically significant pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary disease; 9. Major surgery (requiring general anesthesia) within 6 weeks prior to screening; 10. Historical or current evidence of clinically significant cardiovascular disease defined as any disease that in the opinion of the Investigator would put the safety of the patient at risk through participation or which could affect the efficacy or safety analysis if the disease/condition were to exacerbate during the study. 11. Chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the investigator believes are clinically significant; 12. Unstable liver disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones); 13. History of malignancy within the past 5 years (except for cured basal cell carcinoma or squamous cell carcinoma of skin, cervical carcinoma in situ), or current potential malignancy under evaluation; 14. Abnormal findings on physical examination that an investigator considers to be clinically significant at screening; 15. Chest X-ray (CXR; posterior-anterior) at screening, or in the 12 months prior to screening with clinically significant abnormalities not attributable to COPD; 16. Electrocardiogram (ECG) finding that is significantly abnormal at Screening; 17. Abnormal lab test result, such as eGFR < 30 mL/min, ALT = 2 × upper limit of normal (ULN), alkaline phosphatase and/or bilirubin > 1.5 × ULN, or any other abnormal hematology, biochemistry, or viral serology deemed by an investigator to be clinically significantly abnormal; 18. Use of an experimental drug within 30 days or 5 half-lives prior to screening (whichever is longer), and/or participation in an interventional clinical trial within 30 days prior to screening; 19. Use of an investigational medical device or participation as a subject in a medical device clinical trial within 30 days prior to screening; 20. Intolerance or hypersensitivity to salbutamol or Ensifentrine (RPL554) or any of its excipients/components; 21. Use of traditional Chinese medicine within 2 weeks prior to first dose of Ensifentrine/ Placebo, which with antispasmodic and anti-asthmatic effects and interfering with respirometry test,that would interfere with the study based on the investigator's discretion; 22. Any other reason that the Investigator considers makes the patient unsuitable to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ensifentrine
A dual PDE3/PDE 4 inhibitor
Placebo
Placebo solution

Locations

Country Name City State
China 1st Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Nuance Pharma (shanghai) Co., Ltd Laboratory Corporation of America

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h 12 weeks
Secondary Peak FEV1 over 4 hours post-dose at Week 12 Change from baseline of Peak FEV1 over 4 hours post-dose at Week 12 12 weeks
Secondary Peak FEV1 at Week 6 and Week 24 Change from baseline peak FEV1 6 or 24 weeks
Secondary Morning trough FEV1 at Week 6 and Week 24 Change from baseline morning trough FEV1 6 or 24 weeks
Secondary Average FEV1 AUC0-4h at Week 6 and Week 24 Change from baseline average FEV1 AUC0-4h 6 or 24 weeks
Secondary Average FEV1 AUC0-4h at Week 12 Change from baseline average FEV1 AUC0-4h 12 weeks
Secondary Morning trough FEV1 at Week 12 Change from baseline of morning trough FEV1 at Week 12 12 weeks
Secondary Evening trough FEV1 at Week 12 Change from baseline of evening trough FEV1 at Week 12 12 weeks
Secondary Average FEV1 AUC6-12h at Week 12 Change from baseline of Average FEV1 AUC6-12h at Week 12 12 weeks
Secondary Rescue medication use at Weeks 6, 12 and 24 Change from baseline of Rescue medication use 6, 12 or 24 weeks
Secondary Evaluating-Respiratory Symptoms (E-RS) Total Score at Weeks 6, 12 and 24 Change from baseline of Evaluating-Respiratory Symptoms (E-RS) Total Score 6, 12 or 24 weeks
Secondary SGRQ total score at Weeks 6, 12 and 24 Change from baseline of SGRQ total score 6, 12 or 24 weeks
Secondary SGRQ responder analysis at Weeks 6, 12 and 24 Change from baseline of SGRQ responder analysis 6, 12 or 24 weeks
Secondary TDI total score at Weeks 6, 12 and 24 Change from baseline of TDI total score 6, 12 or 24 weeks
Secondary CAT total score at Weeks 6, 12 and 24 Change from baseline of CAT total score 6, 12 or 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy